The new analysis has confirmed earlier evidence that patients with high Oncotype DX risk scores appear to benefit significantly from added chemotherapy.
Authors concluded that all three assays — Oncotype DX, EndoPredict, and Prosigna — met Canadian thresholds for cost-effectiveness and urged caution in considering the findings.
Meeting presentations supported tweaking the clinical interpretation of Genomic Health's Oncotype DX and bolstered Biotheranostics' Breast Cancer Index.
The randomized data continue to distinguish Genomic Health's test for node-negative women, while new questions come to the fore node-positive disease and other areas of clinical care.
The company's total revenue for the three months ended March 31 was $108.8 million compared to $92.6 million in the first quarter of 2018, exceeding analyst expectations.
A study questioned the cost-effectiveness of the test in clinically low-risk women, but the firm stressed that a wealth of evidence continues to support its use under current guidelines.
A new analysis of the study yielded mixed news for black women, confirming that they suffer worse outcomes, even with the same genetic test results and treatment.
